Leerink Partners analyst Joseph P. Schwartz lowered the price target on WAVE Life Sciences (NASDAQ: WVE) to $25.00 (from $35.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

RBC on WAVE Life Sciences (WVE): 't we continue to see a molecule that is pharmacologically active and remain optimistic'March 27, 2026 5:04 AM WAVE Life Sciences (WVE) PT Lowered to $39 at Clear Street, 'we think ‘007 should find its optimal patient population'March 26, 2026 4:21 PM